Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Jack Herer cannabis oil is a concentrated botanical extract derived from the Jack Herer cannabis strain, a sativa-dominant hybrid originally developed by Sensi Seeds in the 1990s. The oil is characterized by a high concentration of delta-9-tetrahydrocannabinol (THC) and a distinct terpene profile rich in terpinolene, caryophyllene, and pinene. Its primary mechanism of action involves the activation of the endocannabinoid system, specifically acting as a partial agonist at the cannabinoid receptor 1 (CB1) and cannabinoid receptor 2 (CB2). CB1 activation in the central nervous system mediates the drug's psychoactive and analgesic effects, while CB2 activation is associated with anti-inflammatory properties. It is frequently utilized in medical contexts for the management of chronic pain, mood disorders, and fatigue.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Jack Herer cannabis oil.